title: [Malignant hyperthermia].
abstract: Malignant hyperthermia is a serious anesthetic complication, presenting with various manifestations, with high mortality and morbidity. There are several incomplete and abortive forms, and the clinicians must be aware of the possibility of malignant hyperthermia, and recognize the first signs of the hyperthermic crisis hyperthermia, hypermetabolism and muscular rigidity. Screening is performed by in vitro contracture testing on a muscular biopsy. Treatment is based on discontinuation of triggering agents and dantrolene administration, as well as supportive care. Cellular investigations demonstrate that the malignant hyperthermia crisis presents as an intracellular flooding with calcium, leading to an abnormal muscular contracture. Several mutations in particular involving the ryanodine receptor gene have been linked to malignant hyperthermia.
authors.affiliation: Département d'anesthésiologie et de réanimation, Hôpital, régional, Sion.
authors.forename: P
authors.initials: P
authors.lastname: Chastonay
authors.forename: D
authors.initials: D
authors.lastname: Bracco
authors.forename: D
authors.initials: D
authors.lastname: Freymond
authors.forename: P
authors.initials: P
authors.lastname: Ravussin
mesh_terms: D001706:Biopsy; D002675:Child, Preschool; D003620:Dantrolene / Q000627:therapeutic use; D004195:Disease Models, Animal; D006801:Humans; D008297:Male; D008305:Malignant Hyperthermia / Q000175:diagnosis* / Q000209:etiology / Q000378:metabolism / Q000628:therapy*; D008403:Mass Screening; D009125:Muscle Relaxants, Central / Q000627:therapeutic use; D017410:Practice Guidelines as Topic; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D009125:Muscle Relaxants, Central; D003620:Dantrolene